Mesalamine: Clinical Trials

62 trials of Mesalamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed, 8 terminated, 5 unknown, 2 withdrawn. 62 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 362Completed 46, Terminated 8, Unknown 5, Withdrawn 2, Recruiting 1
Phase 27Completed 5, Recruiting 1, Unknown 1

Follow Mesalamine: new trials by email Literature Review of Mesalamine trials Research Report on Mesalamine

Trials (filtered) newest first · largest first

All 62 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Mesalamine, Placebo - Ulcerative Colitis (UC)
Phase 3WithdrawnAbbVie2025-09-152025-08-12
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Mesalazine - Colitis, Ulcerative
Phase 3UnknownFaes Farma, S.A.3762024-03-012023-12-19
Dapagliflozin in Patients With Ulcerative Colitis
Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases
Phase 2 / Phase 3CompletedMostafa Bahaa602023-08-202026-09-21
Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis
Mesalamine, Nifuroxazide - Inflammatory Bowel Diseases
Phase 2 / Phase 3CompletedMostafa Bahaa502023-08-202026-10-13
Fenofibrate in Ulcerative Colitis
Mesalamine, Fenofibrate 160mg - Inflammatory Bowel Diseases
Phase 2 / Phase 3CompletedTanta University602023-02-282026-05-04
Fecal Microbiota Transplantation for Ulcerative Colitis
Fecal microbiota transplantation, Infusion of Saline, 5-Aminosalicylic acid(5-ASA) and/or Prednisone - Ulcerative Colitis, Fecal Microbiota Transplantation
Phase 2 / Phase 3RecruitingGuangzhou First People's Hospital1202019-01-202019-01-15
Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC
Fecal Microbiota Transplantation, Mesalamine Granules, Placebo infusion - Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Phase 3UnknownDayanand Medical College and Hospital202018-12-012019-02-12
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
Budesonide (6 mg), Budesonide (9 mg), Mesalazine (3,600 mg) - Colitis, Ulcerative
Phase 3CompletedFerring Pharmaceuticals2742018-03-022020-06-18
Mercaptopurine Therapy in Ulcerative Colitis
Mercaptopurine (Purinethol), Placebo, Mesalamine - Colitis, Ulcerative
Phase 3UnknownAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1362016-11-012020-01-07
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).
5-ASA, Corticosteroids - Ulcerative Colitis
Phase 3CompletedCentre Hospitalier Universitaire de Saint Etienne1602016-06-132021-08-26
The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer
Mesalazine Sustained-Release Tablets, Riboflavin Sodium Phosphate Injection - Crohn's Disease, Oral Ulcer
Phase 3WithdrawnXijing Hospital of Digestive Diseases2016-03-012023-02-01
Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis
Bio-enhanced Curcumin Soft Gelatin Capsule, 5-Aminosalicylic acid - Ulcerative Colitis
Phase 3UnknownAsian Institute of Gastroenterology, India502016-02-012016-02-23
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
Mesalamine, Placebo - Ulcerative Colitis
Phase 3CompletedFerring Pharmaceuticals2762016-02-012021-11-08
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
Mesalamine, Placebo - Ulcerative Colitis
Phase 3CompletedFerring Pharmaceuticals2282015-10-012021-03-15
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose) - Ulcerative Colitis
Phase 3CompletedShire1072014-12-122021-06-09
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
LT-02, Placebo, Mesalamine - Ulcerative Colitis
Phase 3CompletedDr. Falk Pharma GmbH1502014-10-012020-01-27
Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission
Mesalazine, Tripterygium glycosides - Inflammatory Bowel Diseases, Crohn's Disease
Phase 2 / Phase 3UnknownZhu Weiming402014-01-012014-01-24
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
TP05, Asacol 400 mg - Acute Ulcerative Colitis
Phase 3CompletedTillotts Pharma AG8172013-07-012018-08-08
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
D9421-C capsule 3 mg, Mesalazine tablets - Crohn's Disease
Phase 3CompletedAstraZeneca1232012-02-012016-10-31
Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
Curcumin, 5-aminosalicylic acid - Ulcerative Colitis
Phase 3CompletedSheba Medical Center502011-07-012016-02-12

Showing 20 of 62. Sign in to see all of them.

Conditions studied

Colitis, Ulcerative (35)  ·  Crohn Disease (8)  ·  Inflammatory Bowel Diseases (6)  ·  Colitis (4)  ·  Diverticulitis (4)  ·  Irritable Bowel Syndrome (3)  ·  Ulcer (3)  ·  Abdominal Pain (2)  ·  Diarrhea (2)  ·  Gastrointestinal Diseases (2)  ·  Proctitis (2)  ·  Recurrence (2)  ·  Acute Disease (1)  ·  Colitis, Collagenous (1)  ·  Colitis, Lymphocytic (1)

Sponsors

Dr. Falk Pharma GmbH (10)  ·  Ferring Pharmaceuticals (8)  ·  Shire (6)  ·  Warner Chilcott (5)  ·  Tillotts Pharma AG (4)  ·  SOFAR S.p.A. (3)  ·  Bausch Health Americas, Inc. (2)  ·  Mostafa Bahaa (2)  ·  AbbVie (1)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Asian Institute of Gastroenterology, India (1)  ·  AstraZeneca (1)  ·  Cardiff and Vale University Health Board (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Dayanand Medical College and Hospital (1)

Countries

United States (21)  ·  Germany (13)  ·  Canada (12)  ·  Poland (8)  ·  India (7)  ·  France (6)  ·  Hungary (6)  ·  United Kingdom (6)  ·  Belgium (5)  ·  China (5)  ·  Italy (5)  ·  Netherlands (5)  ·  Romania (5)  ·  Russia (5)  ·  Sweden (5)

Top investigators

Wolfgang Kruis, Professor (3)  ·  Piotr Krzeski, MD (2)  ·  Stephan Miehlke, Professor (2)  ·  Ajit Sood, DM (1)  ·  Alon Lang, MD (1)  ·  Andreas Tromm, Professor (1)  ·  Ashok Tuteja (1)  ·  Axel Dignass, Prof Dr (1)  ·  Barbara Giovanni, Doctor (1)  ·  Brian Feagan, MD (1)

Results publications

PMID 21255059, PMID 21385195, PMID 25038431, PMID 28543263, PMID 28707787, PMID 28707796, PMID 40013523, PMID 17241860, PMID 18272546, PMID 18671232, PMID 18832520, PMID 20551460, PMID 21070781, PMID 21138455, PMID 21453882, PMID 22892337, PMID 23451806, PMID 23528626, PMID 23754545, PMID 24440672, PMID 25419597, PMID 25533646, PMID 25724700, PMID 26898569, PMID 26905266, PMID 28274254, PMID 28568974, PMID 30195447, PMID 31546056, PMID 32889959, PMID 33279779, PMID 37806372, PMID 37855022, PMID 40620467, PMID 41330887

NIH funding

2004 (5), 2015 (3), 2009 (2), 2008 (1)